SEC Form 4 · accession 0000905718-17-000668
DelMar Pharmaceuticals, Inc. · DMPI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Saiid Zarrabian
Director
Period of report
Jul 7, 2017
Accepted (ET)
Jul 11, 2017 · 9:41 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001498382
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Options (Right to Buy)F1 | $2.11 | Jul 7, 2017 | A | 36,000 | A | Jul 7, 2020 | Jul 7, 2027 | Common Stock | 36,000 | 36,000 | D |
| Performance Stock UnitsF2 | — | Jul 7, 2017 | A | 200,000 | A | — | Jul 7, 2022 | Common Stock | 200,000 | 200,000 | D |
Explanation of responses
- F112,000 options vest on June 30, 2018, and 3,000 options vest each three months thereafter starting September 30, 2018.
- F2Subject to stockholder approval of the Company's 2017 Omnibus Equity Incentive Plan at the Company's annual meeting, each performance stock unit represents the right to receive one share of common stock upon vesting of the unit based on targets related to the Company's financial performance.